Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
about
The epigenetic landscape of acute myeloid leukemiaASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repressionEpigenetic regulators and their impact on therapy in acute myeloid leukemiaNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Next generation sequencing of acute myeloid leukemia: influencing prognosis.ASXL1 mutations define a subgroup of patients with acute myeloid leukemia with distinct gene expression profile and poor prognosis: a meta-analysis of 3311 adult patients with acute myeloid leukemia.ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.The distinct biological implications of Asxl1 mutation and its roles in leukemogenesis revealed by a knock-in mouse modelThe changing mutational landscape of acute myeloid leukemia and myelodysplastic syndrome.ASXL genes and RUNX1: an intimate connection?Mutation patterns of 16 genes in primary and secondary acute myeloid leukemia (AML) with normal cytogenetics.Concise review: preleukemic stem cells: molecular biology and clinical implications of the precursors to leukemia stem cellsGene mutations and molecularly targeted therapies in acute myeloid leukemia.An integrated approach of gene expression and DNA-methylation profiles of WNT signaling genes uncovers novel prognostic markers in acute myeloid leukemia.ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group.Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia.A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.Molecular markers in acute myeloid leukaemia.Recent discoveries in molecular characterization of acute myeloid leukemia.The use of molecular genetics to refine prognosis in acute myeloid leukemia.Epigenetic Therapy in Acute Myeloid Leukemia: Current and Future Directions.Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia.ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival.Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis.Pathogenic ASXL1 somatic variants in reference databases complicate germline variant interpretation for Bohring-Opitz Syndrome.Integrated genome-wide genotyping and gene expression profiling reveals BCL11B as a putative oncogene in acute myeloid leukemia with 14q32 aberrations.ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia.Diagnostic application of next-generation sequencing in ZMYM2-FGFR1 8p11 myeloproliferative syndrome: A case report.Highly variable mutational profile of ASXL1 in myelofibrosis.Clonal hematopoiesis as determined by the HUMARA assay is a marker for acquired mutations in epigenetic regulators in older women.Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms.ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification.Familial hematological malignancies: ASXL1 gene investigation.Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience.Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era
P2860
Q21284742-838FBC1C-AB4B-46F3-A184-CA2250C5E832Q24296658-2E9FE8D0-19A8-4291-984D-E060227E792AQ26765402-913ED013-539E-4552-A530-B70866043A90Q26770391-CD2150D7-D501-422B-A5E7-678E17C30678Q27690776-79811DAB-05C0-4E88-947F-D20FE622950AQ27853083-D7E89FC3-B761-4858-B165-A5D4FADA9A10Q33753763-D430DA1A-EB8B-485A-B53A-F27E1135B80DQ33892323-37667156-98C2-4F8E-AE11-395CC5070C4AQ34010735-DD442D43-402D-4F92-8D74-796F168EFADCQ34106779-1791B8B2-6F68-4E1A-ACEE-47E4D02B5053Q34388734-73E03A33-7EA9-4171-8CCC-3E7C509B3566Q34647637-88246EAF-832E-494F-98B8-0877F9B92376Q34647741-C2210E5E-69E1-41DA-9877-42B911F3BE76Q35141163-E2D6C291-1E6F-4E9F-9B5F-77BA2E51D32BQ35146279-9DD151D2-3DEE-4289-BDA2-9E971383C176Q35724527-2164FA1A-73DE-4FB7-9B56-397E31D93546Q35981082-DD8D40B4-EB45-4043-B6E9-E29AFFA81BF2Q37624593-AB8141DE-9B1C-426D-9FF5-D789938B6795Q37995804-FE1173D5-F089-402A-AB63-CC74B5EF4489Q38026007-4A81D0A3-BF93-44C1-87F4-3A56B597548CQ38194465-1EA748B5-2A5E-48AE-B67F-52CF087749CDQ38198569-39A3E1E2-5C67-4213-A855-688D1EF32733Q38537883-211EE066-C75C-4D44-8FC6-944D0852892AQ38703904-B2624524-EDC8-498C-9742-AC9B73F1C9E7Q38711002-6C465D2A-58A2-47C6-8869-12327EC72D33Q38777486-79F1E5BC-20F9-4CAF-9B90-87FCA7D8C873Q38946185-B32EB748-22F4-4559-BB82-4457459B76ADQ39003064-BD3BAE60-5BDF-42BE-A5C9-40CA822D7324Q39147564-B2B2F657-FF52-4565-BFE9-7D44923F55CCQ39163676-7B3427F5-43D8-4078-B444-FF0338106F6AQ40576732-C30AEDC9-EC4A-4C67-AE8E-A2ACB21935CDQ40974422-B1023C9D-9B49-490C-8D12-4B0B28FE707DQ41012858-AE7D0635-8F0D-499A-92D4-A599A5CE5E32Q41452424-647C6417-A938-4265-92AF-BF03A7970680Q42051491-6123F7E6-6AC8-456A-B9A5-114E481EE818Q44113808-8C9C8AED-CDB0-4FBC-BED3-B51041003F16Q53791586-914730C0-D445-47E9-A884-AC51EBFFCC41Q55287855-FE2E0EA5-46BC-4D3F-896A-D93E10509F55Q58734773-C12BAFDE-62F3-49BA-A3DC-B70E567CBC8E
P2860
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
@ast
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
@en
type
label
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
@ast
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
@en
prefLabel
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
@ast
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
@en
P2093
P2860
P1433
P1476
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value.
@en
P2093
Annelieke Zeilemakers
Claudia A J Erpelinck-Verschueren
François G Kavelaars
Jasper E Koenders
Marta Pratcorona
Mathijs A Sanders
Peter J M Valk
Saman Abbas
P2860
P304
P356
10.3324/HAEMATOL.2011.051532
P577
2011-11-04T00:00:00Z